Sugi Predict

Sugi Predict / Compounds / SCHEMBL4662999

SCHEMBL4662999

SCHEMBL4662999

CC(C)(C)OC(=O)N1CCc2ccccc2C1CN

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MTNR1B P49286 1/20 0.47
▸ GHSR Q92847 2/20 0.44
▸ PRMT5 O14744 3/20 0.43
▸ WDR77 Q9BQA1 3/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ DRD1 P21728 1/20 0.41
▸ DRD2 P14416 3/20 0.41
▸ KEAP1 Q14145 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ACE P12821 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30558637 1.00 MTNR1B (0.47) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL18085750 1.00 MTNR1B (0.47) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL31032732 0.90 MTNR1B (0.46) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL12162581 0.89 MTNR1B (0.48) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL18066403 0.89 MEN1 (0.50) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL4664862 0.89 MEN1 (0.50) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL30558539 0.89 MEN1 (0.50) MTNR1BGHSRPRMT5WDR77NR1H2
SCHEMBL11929926 0.88 MTNR1B (0.47) MTNR1BGHSRPRMT5WDR77MEN1
SCHEMBL19056599 0.87 MEN1 (0.51) GHSRPRMT5WDR77NR1H2MEN1
SCHEMBL30429107 0.86 MTNR1B (0.46) MTNR1BGHSRPRMT5WDR77NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111909083-B Inhibitors of histone demethylase 赛尔基因昆蒂赛尔研究公司 2023-08-15 — — CN disclosed
CN-107074823-B Therapeutic compounds and uses thereof 基因泰克公司 2021-05-04 — — CN disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 — — EP disclosed
EP-3160952-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2020-12-02 — — EP disclosed
EP-3741749-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-25 — — EP disclosed
EP-3741749-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-25 — — EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 — — EP disclosed
EP-3738960-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-11-18 — — EP disclosed
CN-111909083-A Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-11-10 — — CN disclosed
CN-106660982-B Histone demethylase inhibitors 赛尔基因昆蒂赛尔研究公司 2020-09-08 — — CN disclosed
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-12-31 — — US disclosed
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-12-31 — — US disclosed
WO-2015200709-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-12-30 — — WO disclosed
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS THE BROAD INSTITUTE, INC. (US) 2014-09-11 — — US disclosed
WO-2013067036-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-05-10 — — WO disclosed
US-20080176838-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) 2008-07-24 — — US disclosed
CN-101005835-A 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-carboxylic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diab SANTHERA PHARMACEUTICALS CH (CH) 2007-07-25 — — CN disclosed
EP-1791536-A1 1-[(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL]-PYRROLIDINE-(2R)-CARBOXYLIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS Santhera Pharmaceuticals (Schweiz) AG (CH) 2007-06-06 — — EP disclosed
WO-2005120494-A1 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2005-12-22 — — WO disclosed
EP-1604662-A1 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) 2005-12-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376169-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM6A, KDM1A MTNR1B 1576/4885GHSR 3337/4885PRMT5 56/4885
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS KEAP1, NFE2L2, HMOX1 MTNR1B 414/4885GHSR 4299/4885PRMT5 1951/4885
US-20080176838-A1 Dpp-IV Inhibitors DPP4, DPP9, DPP7 MTNR1B 308/4885GHSR 232/4885PRMT5 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.